Loading...
•
Mar 31, 2023
Regeneron Q1 2023 Earnings Report
Regeneron's financial performance was marked by a revenue increase driven by key products and strategic collaborations, alongside significant pipeline advancements and regulatory milestones.
Key Takeaways
Regeneron reported a 7% increase in first quarter 2023 revenues, reaching $3.16 billion. The company saw growth in Dupixent global sales and U.S. EYLEA sales, accompanied by progress in its clinical pipeline with multiple regulatory approvals and positive trial results. GAAP diluted EPS was $7.17, and non-GAAP diluted EPS was $10.09, including an unfavorable $0.42 impact from acquired IPR&D charge.
Total revenues increased by 7% to $3.16 billion compared to Q1 2022.
Dupixent global net sales (recorded by Sanofi) increased 37% to $2.49 billion compared to Q1 2022.
GAAP diluted EPS was $7.17 and non-GAAP diluted EPS was $10.09, including an unfavorable $0.42 impact from acquired IPR&D charge.
Multiple FDA and EC approvals were achieved across five products, expanding the reach of Regeneron's medicines.
Revenue by Segment
Forward Guidance
Regeneron's full year 2023 financial guidance includes updates to GAAP R&D, GAAP SG&A, GAAP gross margin on net product sales, COCM, capital expenditures, and GAAP effective tax rate.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...